Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CFTR negatively reprograms Th2 cell responses, and CFTR potentiation restrains allergic airway inflammation
Mark Rusznak, Christopher M. Thomas, Jian Zhang, Shinji Toki, Weisong Zhou, Masako Abney, Danielle M. Yanda, Allison E. Norlander, Craig A. Hodges, Dawn C. Newcomb, Mark H. Kaplan, R. Stokes Peebles Jr., Daniel P. Cook
Mark Rusznak, Christopher M. Thomas, Jian Zhang, Shinji Toki, Weisong Zhou, Masako Abney, Danielle M. Yanda, Allison E. Norlander, Craig A. Hodges, Dawn C. Newcomb, Mark H. Kaplan, R. Stokes Peebles Jr., Daniel P. Cook
View: Text | PDF
Research Article Immunology Inflammation Pulmonology

CFTR negatively reprograms Th2 cell responses, and CFTR potentiation restrains allergic airway inflammation

  • Text
  • PDF
Abstract

Type 2 inflammatory diseases, including asthma, sinusitis, and allergic bronchopulmonary aspergillosis, are common in cystic fibrosis (CF). CD4+ Th2 cells promote these diseases through secretion of IL-4, IL-5, and IL-13. Whether the CF transmembrane conductance regulator (CFTR), the mutated protein in CF, has a direct effect on Th2 development is unknown. Using murine models of CFTR deficiency and human CD4+ T cells, we show that CD4+ T cells expressed Cftr transcript and CFTR protein following activation. Loss of T cell CFTR expression increased Th2 cytokine production compared with control cells. Mice with CFTR-deficient T cells developed increased allergic airway disease to Alternaria alternata extract compared with control mice. Culture of CFTR-deficient Th2 cells demonstrated increased IL-4Rα expression and increased sensitivity to IL-4 with greater induction of GATA3 and IL-13 compared with control Th2 cell cultures. The CFTR potentiator ivacaftor reduced allergic inflammation and type 2 cytokine secretion in bronchoalveolar lavage of humanized CFTR mice following Alternaria alternata extract challenge and decreased Th2 development in human T cell culture. These data support a direct role of CFTR in regulating T cell sensitivity to IL-4 and demonstrate a potential CFTR-specific therapeutic strategy for Th2 cell–mediated allergic disease.

Authors

Mark Rusznak, Christopher M. Thomas, Jian Zhang, Shinji Toki, Weisong Zhou, Masako Abney, Danielle M. Yanda, Allison E. Norlander, Craig A. Hodges, Dawn C. Newcomb, Mark H. Kaplan, R. Stokes Peebles Jr., Daniel P. Cook

×

Figure 2

Loss of CFTR increases Th2 polarization and effector function.

Options: View larger image (or click on image) Download as PowerPoint
Loss of CFTR increases Th2 polarization and effector function.
(A) Schem...
(A) Schematic diagram showing isolation and stimulation of naive CD4+ T cells. (B and C) IL-5 and IL-13 by ELISA in cellular supernatant from Cftr+/+ and Cftr−/− CD4+ T cells grown in culture stimulated with mouse IL-4 (n = 5 mice per genotype). (D) Representative gating strategy for IL-13 expression in cultured Cftr+/+ and Cftr−/− CD4+ T cell populations gated on live lymphoid cells. (E) IL-13 median fluorescence intensity (MFI) of cultured Cftr+/+ and Cftr−/− CD4+ T cells (n = 5 mice per genotype). (F) IL-13 by ELISA in cellular supernatant from Cftr+/+ CD4+ T cells grown in culture with the CFTR inhibitor, GlyH-101, or control vehicle (DMSO) stimulated with mouse IL-4. (G and H) IL-5 and IL-13 by ELISA in cellular supernatant from mouse CD4+ T cells expressing either wild-type human CFTR or hCFTRΔF508 grown in culture with Elexacaftor/Tezacaftor/ Ivacaftor (ETI) or DMSO control (n = 5 mice per genotype per condition). Data are shown as mean ± SD. Statistical analysis were performed using unpaired Student’s t test (B, C, E, and F) and by 1-way ANOVA (G and H) followed by Tukey’s honestly significant difference (HSD) post hoc test for multiple comparisons. *P < 0.05, **P < 0.01, and ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts